跳至主要内容
临床试验/NL-OMON21913
NL-OMON21913尚未招募不适用

In vitro potency of clinically used antiplatelet drugs in patients with Metabolic dysfunction Associated Fatty Liver Disease

MCG0 个研究点目标入组 160 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Inclusion criteria study groups:
  • = 18 years of age
  • Signed informed consent
  • Some degree of liver steatosis and fibrosis (F1-F4) with or without diagnosis of diabetes mellitus type 2
  • Inclusion criteria control group:
  • = 18 years of age
  • Signed informed consent

排除标准

  • Underlying liver disease with other aetiology than MAFLD
  • Use of anti-platelet (salicylates, P2Y12 inhibitors, dipyridamole) or anti-hemostatic (heparins, vitamin K antagonists, direct oral anticoagulants) drugs
  • Use of Non-Steroid Anti-Inflammatory Drugs 4 days prior to inclusion
  • Documented history of hereditary thrombophilia or haemophilia
  • Current malignancy
  • Pre-existing immunosuppressive status (HIV positivity, previous solid organ transplant)
  • Transfusion of blood products 7 days prior to inclusion
  • Not willing to be notified of FibroScan results

研究者

发起方
MCG

相似试验